Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Myriad Genetics announces publication of two riskScore analyses » 07:11
07/07/20
07/07
07:11
07/07/20
07:11
MYGN

Myriad Genetics

$11.85 /

+0.325 (+2.82%)

Myriad Genetics announced…

Myriad Genetics announced two recent publications validating the polygenic risk score, or PRS, component of Myriad's breast cancer risk stratification tool riskScore. The publications clinically validate both the ability of the PRS component of riskScore to predict breast cancer risk in asymptomatic women and modify risk estimations for patients identified with pathogenic mutations. The first study published in JCO Precision Oncology described the PRS component of riskScore in over 150,000 women. It showed that independent of other hereditary breast cancer gene mutations, Myriad's polygenic risk score can add value and precision to breast cancer risk estimates. The PRS was highly associated with breast cancer risk with an odds ratio of 1.47 per unit standard deviation in the PRS. This translated to women in the top PRS percentile having a three-fold higher risk of breast cancer than an average risk patient. The second study published in the Journal of the American Medical Association Network Open demonstrates the ability of Myriad's polygenic risk score to improve breast cancer risk stratification in women diagnosed with pathogenic mutations in common breast cancer genes. The study evaluated over 150,000 patients and approximately 10,000 patients who were carriers of pathogenic mutations in the BRCA1, BRCA2, CHEK2, ATM and PALB2 genes who were tested at Myriad. The study demonstrated that patients with high penetrant genes such as BRCA1 and BRCA2 did not warrant changes in clinical management; however, breast cancer risks in patients with moderate penetrant genes such as CHEK2, ATM and PALB2 could vary significantly, warranting different clinical management considerations. For example, patients with a PALB2 mutation historically have been assessed to have an approximately 50% lifetime risk for breast cancer. However, after incorporating the data from Myriad's 86 single nucleotide polymporphism riskScore test, patient risks varied between 26% to 79%.

ShowHide Related Items >><<
MYGN Myriad Genetics
$11.85 /

+0.325 (+2.82%)

MYGN Myriad Genetics
$11.85 /

+0.325 (+2.82%)

06/11/20 Piper Sandler
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
05/06/20 Piper Sandler
Myriad Genetics price target lowered to $14 from $20 at Piper Sandler
03/06/20 JPMorgan
Myriad Genetics price target lowered to $14 from $17 at JPMorgan
MYGN Myriad Genetics
$11.85 /

+0.325 (+2.82%)

MYGN Myriad Genetics
$11.85 /

+0.325 (+2.82%)

Hot Stocks
Myriad Genetics announces collaboration with OptraHealth for Gene ChatBOT » 07:15
07/06/20
07/06
07:15
07/06/20
07:15
MYGN

Myriad Genetics

$11.53 /

+0.275 (+2.44%)

Myriad Genetics announced…

Myriad Genetics announced a new collaboration with OptraHealth to implement a cognitive ChatBOT named Gene to provide genetic and financial assistance information to prospective patients. Gene is an AI-powered, HIPAA-compliant knowledge platform for genetic health with BOT interfaces and can answer over 500,000 health related questions pertaining to hereditary cancer. Gene interfaces with Myriad's online hereditary cancer quiz, which is now taken by approximately one million people per year. Gene will interactively engage individuals online, providing them with education about hereditary cancer prior to taking an online assessment to determine if they may be a candidate for genetic testing. For those who complete the preliminary assessment and meet criteria for further evaluation, Gene will automate a pre-test process that sends an educational link that displays interactive multimedia content and gives the option to start a live conversation with a patient educator, who is a certified genetic counselor. Gene can also assist in finding a healthcare provider who can help a patient make a decision whether testing is appropriate and then order testing if so. Myriad plans on launching the Gene chatbot for its Foresight and Prequel prenatal tests and for companion diagnostic testing in oncology later this calendar year.

ShowHide Related Items >><<
MYGN Myriad Genetics
$11.53 /

+0.275 (+2.44%)

MYGN Myriad Genetics
$11.53 /

+0.275 (+2.44%)

06/11/20 Piper Sandler
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
05/06/20 Piper Sandler
Myriad Genetics price target lowered to $14 from $20 at Piper Sandler
03/06/20 JPMorgan
Myriad Genetics price target lowered to $14 from $17 at JPMorgan
MYGN Myriad Genetics
$11.53 /

+0.275 (+2.44%)

MYGN Myriad Genetics
$11.53 /

+0.275 (+2.44%)

Hot Stocks
Myriad Genetics launches GeneSight Psychotropic patient collection kit » 07:26
07/01/20
07/01
07:26
07/01/20
07:26
MYGN

Myriad Genetics

$11.33 /

+0.27 (+2.44%)

Myriad Genetics announced…

Myriad Genetics announced the launch of a new patient home collection kit for the GeneSight Psychotropic test. The kit allows the DNA sample collection typically administered in a clinician's office to be completed at home. The new direct-to-patient collection kit must still be ordered by a licensed healthcare provider. Clinicians who have determined that GeneSight is right for their patient may order the test through the secure, online GeneSight portal and request that the kit be sent directly to the patient. Once the patient receives the kit, they follow a clear process with step-by-step instructions. The kit utilizes a buccal, or cheek swab, the patient can use to collect DNA from the inside of their cheeks. After collecting the sample, the patient puts the swab into a confidential, pre-paid and pre-addressed shipping envelope to return it to the Myriad Neuroscience CLIA and CAP Accredited lab for processing. In approximately two days, the ordering clinician receives the GeneSight report via the secure clinician portal.

ShowHide Related Items >><<
MYGN Myriad Genetics
$11.33 /

+0.27 (+2.44%)

MYGN Myriad Genetics
$11.33 /

+0.27 (+2.44%)

06/11/20 Piper Sandler
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
05/06/20 Piper Sandler
Myriad Genetics price target lowered to $14 from $20 at Piper Sandler
03/06/20 JPMorgan
Myriad Genetics price target lowered to $14 from $17 at JPMorgan
MYGN Myriad Genetics
$11.33 /

+0.27 (+2.44%)

MYGN Myriad Genetics
$11.33 /

+0.27 (+2.44%)

Hot Stocks
Myriad Genetics announces publication of study on myPath melanoma » 07:07
06/25/20
06/25
07:07
06/25/20
07:07
MYGN

Myriad Genetics

$11.11 /

-1.13 (-9.23%)

Myriad Genetics announced…

Myriad Genetics announced that a new study published in Future Medicine demonstrates the ability of myPath Melanoma to accurately classify skin lesions ruled indeterminate by standard pathological review. The study evaluated 181 skin lesions of which 125 were ruled indeterminate by at least one of seven blinded dermatopathologists who reviewed the samples. The samples were linked to known real world outcomes with 43 percent of samples representing malignant melanomas. Importantly, myPath Melanoma demonstrated 90.4 percent sensitivity and 95.5 percent specificity in the indeterminate sample cohort and 93.8 percent sensitivity and 96.2 percent specificity when evaluating the entire sample cohort. This data is consistent with multiple other clinical validation studies for myPath Melanoma which have demonstrated the ability of the test to delineate melanoma from benign skin lesions with high diagnostic accuracy.

ShowHide Related Items >><<
MYGN Myriad Genetics
$11.11 /

-1.13 (-9.23%)

MYGN Myriad Genetics
$11.11 /

-1.13 (-9.23%)

06/11/20 Piper Sandler
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
05/06/20 Piper Sandler
Myriad Genetics price target lowered to $14 from $20 at Piper Sandler
03/06/20 JPMorgan
Myriad Genetics price target lowered to $14 from $17 at JPMorgan
MYGN Myriad Genetics
$11.11 /

-1.13 (-9.23%)

MYGN Myriad Genetics
$11.11 /

-1.13 (-9.23%)

Conference/Events
Myriad Genetics management to meet virtually with BTIG » 04:55
06/24/20
06/24
04:55
06/24/20
04:55
MYGN

Myriad Genetics

$12.24 /

-0.22 (-1.77%)

Virtual Meeting to be…

Virtual Meeting to be held on June 24 hosted by BTIG.

ShowHide Related Items >><<
MYGN Myriad Genetics
$12.24 /

-0.22 (-1.77%)

MYGN Myriad Genetics
$12.24 /

-0.22 (-1.77%)

06/11/20 Piper Sandler
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
05/06/20 Piper Sandler
Myriad Genetics price target lowered to $14 from $20 at Piper Sandler
03/06/20 JPMorgan
Myriad Genetics price target lowered to $14 from $17 at JPMorgan
MYGN Myriad Genetics
$12.24 /

-0.22 (-1.77%)

MYGN Myriad Genetics
$12.24 /

-0.22 (-1.77%)

Conference/Events
Myriad Genetics management to meet virtually with BTIG » 12:15
06/22/20
06/22
12:15
06/22/20
12:15
MYGN

Myriad Genetics

$12.40 /

+0.29 (+2.39%)

Virtual Meeting to be…

Virtual Meeting to be held on June 24 hosted by BTIG.

ShowHide Related Items >><<
MYGN Myriad Genetics
$12.40 /

+0.29 (+2.39%)

MYGN Myriad Genetics
$12.40 /

+0.29 (+2.39%)

06/11/20 Piper Sandler
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
05/06/20 Piper Sandler
Myriad Genetics price target lowered to $14 from $20 at Piper Sandler
03/06/20 JPMorgan
Myriad Genetics price target lowered to $14 from $17 at JPMorgan
MYGN Myriad Genetics
$12.40 /

+0.29 (+2.39%)

MYGN Myriad Genetics
$12.40 /

+0.29 (+2.39%)

MYGN Myriad Genetics
$12.40 /

+0.29 (+2.39%)

Over a month ago
Hot Stocks
Myriad Genetics announces favorable coverage policies for Prolaris » 07:28
06/15/20
06/15
07:28
06/15/20
07:28
MYGN

Myriad Genetics

$12.01 /

-0.355 (-2.87%)

Myriad Genetics announced…

Myriad Genetics announced that the company has received favorable coverage decisions for Prolaris from three new commercial health plans including one of the top five national providers of health insurance. The first new coverage policy which can be viewed here became effective June 8, 2020, the second new coverage policy becomes effective on June 15, 2020 and the third new coverage policy which can be viewed here becomes effective on July 31, 2020. In combination, these health plans cover approximately 26 million commercial lives bringing total commercial coverage for Prolaris up to 55 million lives.

ShowHide Related Items >><<
MYGN Myriad Genetics
$12.01 /

-0.355 (-2.87%)

MYGN Myriad Genetics
$12.01 /

-0.355 (-2.87%)

06/11/20 Piper Sandler
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
05/06/20 Piper Sandler
Myriad Genetics price target lowered to $14 from $20 at Piper Sandler
03/06/20 JPMorgan
Myriad Genetics price target lowered to $14 from $17 at JPMorgan
MYGN Myriad Genetics
$12.01 /

-0.355 (-2.87%)

MYGN Myriad Genetics
$12.01 /

-0.355 (-2.87%)

MYGN Myriad Genetics
$12.01 /

-0.355 (-2.87%)

Recommendations
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler » 15:22
06/11/20
06/11
15:22
06/11/20
15:22
MYGN

Myriad Genetics

$13.01 /

-2.59 (-16.60%)

Piper Sandler analyst…

Piper Sandler analyst William Quirk noted that Palmetto GBA, one of the administrative contractors for the Centers for Medicare & Medicaid Services, issued a final local coverage determination, or LCD, for pharmacogenomic testing that establishes coverage for single and multi-gene panels. However, Palmetto said there is insufficient data to support coverage of combinatorial tests such as Myriad Genetics' GeneSight. While he believes GeneSight could be covered under the multi-gene panel coverage, he also believes some components of the test may not be reimbursed, Quirk tells investors. He continues to see limited visibility given that the LCD language is unclear about GeneSight, leading Quirk to maintain a Neutral rating and $14 price target on Myriad shares.

ShowHide Related Items >><<
MYGN Myriad Genetics
$13.01 /

-2.59 (-16.60%)

MYGN Myriad Genetics
$13.01 /

-2.59 (-16.60%)

05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
05/06/20 Piper Sandler
Myriad Genetics price target lowered to $14 from $20 at Piper Sandler
03/06/20 JPMorgan
Myriad Genetics price target lowered to $14 from $17 at JPMorgan
02/07/20 JPMorgan
Myriad Genetics price target lowered to $17 from $20 at JPMorgan
MYGN Myriad Genetics
$13.01 /

-2.59 (-16.60%)

MYGN Myriad Genetics
$13.01 /

-2.59 (-16.60%)

MYGN Myriad Genetics
$13.01 /

-2.59 (-16.60%)

Hot Stocks
Myriad Genetics 'encouraged' by issuance of pharmacogenomic LCD by Palmetto GBA » 11:27
06/11/20
06/11
11:27
06/11/20
11:27
MYGN

Myriad Genetics

$12.56 /

-3.04 (-19.49%)

Myriad Genetics…

Myriad Genetics acknowledges the release of a final local coverage determination for pharmacogenomic testing by Palmetto GBA, one of the administrative contractors for the Centers for Medicare & Medicaid Services. The new LCD does not restrict PGx testing by provider type as long as the provider has the licensure, qualifications, and necessary experience / training to both diagnose the condition being treated and also to prescribe medications. The LCD provides coverage across a range of psychiatric conditions.The new LCD is a limited coverage policy for PGx testing that establishes coverage for single-gene and multi-gene tests. While Palmetto states that there are insufficient data to support coverage of combinatorial tests, the LCD notes "that combinatorial tests are a subtype of multi-gene PGx tests, and there may be components within those tests that are necessary and reasonable and thus may be covered." Though this Palmetto GBA LCD is final, details of its application to GeneSight Psychotropic testing await action by CGS Administrators, LLC, the Medicare Administrative Contractor for the GeneSight test. "We are encouraged by the issuance of a pharmacogenomic LCD with broad coverage of tests ordered by any licensed physician for the treatment of a range of psychiatric conditions," said Mark S. Verratti, president of Myriad Neuroscience and Myriad Autoimmune. "We believe GeneSight is covered under the new LCD as a multi-gene panel and await a Local Coverage Article for GeneSight and specific action by CGS. Multiple clinical studies have demonstrated the clinical value of the GeneSight Psychotropic combinatorial test."

ShowHide Related Items >><<
MYGN Myriad Genetics
$12.56 /

-3.04 (-19.49%)

MYGN Myriad Genetics
$12.56 /

-3.04 (-19.49%)

05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
05/06/20 Piper Sandler
Myriad Genetics price target lowered to $14 from $20 at Piper Sandler
03/06/20 JPMorgan
Myriad Genetics price target lowered to $14 from $17 at JPMorgan
02/07/20 JPMorgan
Myriad Genetics price target lowered to $17 from $20 at JPMorgan
MYGN Myriad Genetics
$12.56 /

-3.04 (-19.49%)

MYGN Myriad Genetics
$12.56 /

-3.04 (-19.49%)

MYGN Myriad Genetics
$12.56 /

-3.04 (-19.49%)

Hot Stocks
Myriad Genetics announces publication of study on GeneSight Psychotropic test » 07:09
06/08/20
06/08
07:09
06/08/20
07:09
MYGN

Myriad Genetics

$16.48 /

+0.57 (+3.58%)

Myriad Genetics announced…

Myriad Genetics announced a newly published study in Psychiatry Research. The study demonstrated the GeneSight Psychotropic test is better at predicting citalopram and escitalopram blood concentrations when compared to single-gene testing. The GeneSight test uses a combinatorial pharmacogenomic approach, which evaluates how variations in multiple genes may influence an individual's outcomes with certain medications. The new study assessed 191 patients from the GUIDED clinical study who were taking either citalopram or escitalopram at the time of their screening visit, had their dose specified, and provided a blood sample. Citalopram and escitalopram are routine first and second line treatments for major depressive disorder. Current Clinical Pharmacogenetics Implementation Consortium guidelines make recommendations for citalopram based upon CYP2C19 metabolizer status. However, scientific evidence supports the role of additional genes in citalopram metabolism. In the study, if testing was conducted on CYP2C19 alone, fewer patients with decreased metabolism for citalopram would have been identified. However, the combinatorial approach used by the GeneSight Psychotropic test identified more patients with decreased metabolism. Accordingly, more patients who could benefit from clinically actionable recommendations were identified. Furthermore, combinatorial pharmacogenomic testing explained more variance in citalopram blood levels when compared to single-gene testing.

ShowHide Related Items >><<
MYGN Myriad Genetics
$16.48 /

+0.57 (+3.58%)

MYGN Myriad Genetics
$16.48 /

+0.57 (+3.58%)

05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
05/06/20 Piper Sandler
Myriad Genetics price target lowered to $14 from $20 at Piper Sandler
03/06/20 JPMorgan
Myriad Genetics price target lowered to $14 from $17 at JPMorgan
02/07/20 JPMorgan
Myriad Genetics price target lowered to $17 from $20 at JPMorgan
MYGN Myriad Genetics
$16.48 /

+0.57 (+3.58%)

MYGN Myriad Genetics
$16.48 /

+0.57 (+3.58%)

MYGN Myriad Genetics
$16.48 /

+0.57 (+3.58%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.